Were you prescribed the drug Actos for type 2 diabetes and were later diagnosed with bladder cancer? You may be entitled to a substantial settlement.
Call me today and I’ll Make Them Pay!®
Actos is a drug that is used to help control blood sugar in individuals with type 2 diabetes. Actos (pioglitazone) is manufactured by Takeda Pharmaceuticals and sold in the US, and worldwide.
In 2011, France and Germany pulled Actos from their markets. Soon thereafter, the U.S. FDA (Food and Drug Administration) warned that people who took Actos for more than one year have a 40% greater chance of developing bladder cancer than type 2 diabetics who were not prescribed Actos.
The British Medical Journal (BMJ) published a study in 2012 that concluded Actos (pioglitazone) is associated with an increased risk of bladder cancer for individuals who used Actos for more than 24 months, and for people who received cumulative doses of more than 28,000 mg.
- More than 2 million patients filled a prescription for a pioglitazone-containing product.
- Sold as a single-ingredient product under the brand-named Actos.
- Pioglitazone is also sold in combination with metformin, which is also a type 2 diabetic drug. These combination drugs are named Actoplus Met, Actoplus Met XR and Duetact/Glimepiride.
- Actos is marketed to be used in association with diet and exercise to control blood sure levels in adults with type 2 diabetes.
Lawsuits allege Actos was defectively designed and unreasonably dangerous, and the manufacturers and distributors of Actos failed to adequately warn the public of know dangers.
If you took Actos, or other combination drug containing pioglitazone for more than 24 months, or had cumulative dosage of more than 28,000 mg and then developed bladder cancer, you need to call me today!
I have the experience and financial resources to take on large corporations. I have spent the last 41 years fighting for victims injured by defective drugs, and have obtained hundreds of millions of dollars for my clients.